REXADEV Trademark

Trademark Overview


On Monday, August 22, 2016, a trademark application was filed for REXADEV with the United States Patent and Trademark Office. The USPTO has given the REXADEV trademark a serial number of 87146623. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 7, 2020. This trademark is owned by Amgen Inc.. The REXADEV trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations, biosimilars and pharmaceutical substances used for the treatment of bone, joint, vertebral column, intestine, colon, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, blood cells, blood vessel, and blood diseases and disorders; pharmaceutical preparations, biosimilars and pharmaceutical substances for the treatment of autoimmune, immune system, inflammatory, inflammatory bowel, gastrointestinal, genitourinary, musculoskeletal, dermatological, pulmonary, respiratory, oncological, hepatological, lymphomas, leukemias, ophthalmic, transplant rejection, cardiovascular, endocrine, neurological, sleep, muscular, and psychiatric diseases and disorders; pharmaceutical preparations and biosimilars, namely, pharmaceutical preparations and pharmaceutical substances used for the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis r...
rexadev

General Information


Serial Number87146623
Word MarkREXADEV
Filing DateMonday, August 22, 2016
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, September 7, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 6, 2017

Trademark Statements


Goods and Servicespharmaceutical preparations, biosimilars and pharmaceutical substances used for the treatment of bone, joint, vertebral column, intestine, colon, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, blood cells, blood vessel, and blood diseases and disorders; pharmaceutical preparations, biosimilars and pharmaceutical substances for the treatment of autoimmune, immune system, inflammatory, inflammatory bowel, gastrointestinal, genitourinary, musculoskeletal, dermatological, pulmonary, respiratory, oncological, hepatological, lymphomas, leukemias, ophthalmic, transplant rejection, cardiovascular, endocrine, neurological, sleep, muscular, and psychiatric diseases and disorders; pharmaceutical preparations and biosimilars, namely, pharmaceutical preparations and pharmaceutical substances used for the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis related arthritis, osteoarthritis, peripheral spondyloarthritis, polymyalgia rheumatic, spondyloarthropathies, acute disc prolapse, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Intestinal Behçet's Disease, chronic pouchitis, small bowel lesions, Hermansky-Pudlak syndrome, autoimmune pancreatitis, multiple myeloma, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, chronic inflammatory demyelinating polyneuropathy, autoimmune anemia, autoimmune hemolytic anemia, pure red cell aplasia, idiopathic thrombocytopenic purpura, Evans syndrome, type 1 diabetes mellitus, Sjogren's syndrome, encephalitis, IgG4-related disease, Devic's disease, myositis, psoriasis, psoriasis vulgaris, psoriasis arthropica, plaque psoriasis, palmoplantar psoriasis, hidradenitis suppurativa, bullous skin disorder, pemphigus, pemphigoid, kawasaki disease, interstitial cystitis, sleep apnea, sarcoidosis, retinal vascular disorders, age-related macular degeneration, refractory diabetic macular edema, uveitis, childhood uveitis, uveitic macular edema, choroidal neovascularization, Graves' ophthalmopathy, pyoderma gangrenosum, giant cell arteritis, Netherton syndrome, anaplastic thyroid cancer, breast cancer, ovarian cancer, cervical cancer, gastric cancer, colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, renal cell carcinoma, head and neck cancer, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, lymphocyte predominant subtype of Hodgkin's Lymphoma, vasculitis, granulomatosis with polyangiitis, microscopic polyangiitis, graft-versus-host disease, graft-versus-host disease following allogenic hematopoietic stem cell transplantation, graft-versus-host disease following keratoprosthesis, kidney transplant, asthma, chronic fatigue syndrome, major depression, and bipolar depression

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, August 25, 2016
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAmgen Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 913201799

Party NameAmgen Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 913201799

Trademark Events


Event DateEvent Description
Tuesday, September 8, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, September 7, 2020ABANDONMENT - NO USE STATEMENT FILED
Saturday, November 23, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 22, 2019EXTENSION 5 GRANTED
Wednesday, November 20, 2019EXTENSION 5 FILED
Friday, November 22, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, November 20, 2019TEAS EXTENSION RECEIVED
Tuesday, May 28, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, May 24, 2019EXTENSION 4 GRANTED
Friday, May 24, 2019EXTENSION 4 FILED
Friday, May 24, 2019TEAS EXTENSION RECEIVED
Thursday, March 7, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, March 7, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, January 24, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 22, 2019EXTENSION 3 GRANTED
Tuesday, January 22, 2019EXTENSION 3 FILED
Tuesday, January 22, 2019TEAS EXTENSION RECEIVED
Saturday, July 14, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 12, 2018EXTENSION 2 GRANTED
Thursday, July 12, 2018EXTENSION 2 FILED
Thursday, July 12, 2018TEAS EXTENSION RECEIVED
Saturday, January 27, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 25, 2018EXTENSION 1 GRANTED
Thursday, January 25, 2018EXTENSION 1 FILED
Thursday, January 25, 2018TEAS EXTENSION RECEIVED
Tuesday, August 1, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 6, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 6, 2017PUBLISHED FOR OPPOSITION
Wednesday, May 17, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, April 26, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, April 25, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, April 24, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, April 24, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, April 24, 2017TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, October 31, 2016NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, October 31, 2016NON-FINAL ACTION E-MAILED
Monday, October 31, 2016NON-FINAL ACTION WRITTEN
Friday, October 28, 2016ASSIGNED TO EXAMINER
Thursday, August 25, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, August 25, 2016NEW APPLICATION ENTERED IN TRAM